FibroGen down as neuromuscular disorder drug fails in late-stage study

Kyntra Bio

29/08/2023 21:58

** FibroGen Inc's shares  FGEN.O  fall 14% to $1.1 in
aftermarket trading
    ** The drug developer said its experimental drug to treat
ambulatory patients with Duchenne muscular dystrophy (DMD)
failed to meet the main goal in a late-stage study 
    ** The drug also failed to meet the secondary goals 
    ** DMD causes progressive muscle failure that mainly affects
boys, with symptoms showing at an early age
    ** FGEN's drug had also failed to meet the main goal in DMD
patients with non-ambulatory forms of the disorder and chronic
lung disease, idiopathic pulmonary fibrosis, in June
    ** As of last close, stock had fallen ~92% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))